Annals of the Russian academy of medical sciencesAnnals of the Russian academy of medical sciencesВестник Российской академии медицинских наук0869-60472414-3545"Paediatrician" Publishers LLC13110.15690/vramn.v68i11.852SHORT MESSAGESКРАТКИЕ СООБЩЕНИЯWHICH PATIENTS WITH OVARIAN CANCER SHOWS THE COMBINATION OF TRABECTEDIN WITH PEGYLATED LIPOSOMAL DOXORUBICINКАКИМ БОЛЬНЫМ РАКОМ ЯИЧНИКА ПОКАЗАНА КОМБИНАЦИЯ ТРАБЕКТЕДИНА С ПЕГИЛИРОВАННЫМ ЛИПОСОМАЛЬНЫМ ДОКСОРУБИЦИНОМKhokhlovaS. V.ХохловаС. В.
Russian Federation

MD, senior research scientist of Chemotherapy Department of FSBI “N.N. Blokhin Russian Cancer Research Center” of RAMS. Address: 24, Kashirskoe Highway, Moscow, RF, 115478; tel.: +7 (495) 324-19-19

svkhokhlova@mail.ruCherkasovaM. V.ЧеркасоваМ. В.
Russian Federation

postgraduate of the Department of Oncology of RMAPE. Address: 2/1, Barrikadnaya Street, Moscow, RF, 123995; tel.: (499) 252-21-04

m_cherkasova@mail.ruOrelN. F.ОрелН. Ф.
Russian Federation

PhD, leading research scientist of Chemotherapy Department of FSBI “N.N. Blokhin Russian Cancer Research Center” of RAMS, professor of the Department of Oncology of RMAPE. Address: 24, Kashirskoe Highway, Moscow, RF, 115478; tel.: +7 (495) 324-19-19

orel.nad@yandex.ruLimarevaS. V.ЛимареваС. В.
Russian Federation

MD, research scientist of Chemotherapy Department of FSBI “N.N. Blokhin Russian Cancer Research Center” of RAMS. Address: 24, Kashirskoe Highway, Moscow, RF, 115478; tel.: +7 (495) 324-19-19

limareva@yandex.ruBazaevaI. Ya.БазаеваИ. Я.
Russian Federation

postgraduate of Chemotherapy Department of FSBI “N.N. Blokhin Russian Cancer Research Center” of RAMS. Address: 24, Kashirskoe Highway, Moscow, RF, 115478; tel.: +7 (495) 324-19-19

irinabazaeva@rambler.ruGorbunovaV. A.ГорбуноваВ. А.
Russian Federation

PhD, professor, Head of Chemotherapy Department of FSBI “N.N. Blokhin Russian Cancer Research Center” of RAMS. Address: 24, Kashirskoe Highway, Moscow, RF, 115478; tel.: +7 (495) 324-19-19

veragorbounova@mail.ruN.N. Blokhin Russian Cancer Research Center of RAMS, Moscow, Russian FederationРОНЦ им. Н.Н. Блохина РАМН, Москва, Российская ФедерацияRussian Medical Academy of Postgraduate Education, Moscow, Russian FederationРоссийская медицинская академия последипломного образования МЗ РФ, Москва, Российская ФедерацияN.N. Blokhin Russian Cancer Research Center of RAMS, Moscow, Russian Federation Russian Medical Academy of Postgraduate Education, Moscow, Russian FederationРОНЦ им. Н.Н. Блохина РАМН, Москва, Российская Федерация Российская медицинская академия последипломного образования МЗ РФ, Москва, Российская Федерация121120136811Vestnik Rossiiskoi akademii medetsinskikh nauk / Annals of the Russian academy of medical sciencesВестник Российской академии медицинских наук11512107082015Copyright ©; 1970, "Paediatrician" Publishers LLCCopyright ©; 1970, Издательство "Педиатръ"1970"Paediatrician" Publishers LLCИздательство "Педиатръ"https://vestnikramn.spr-journal.ru/jour/about/submissionshttps://vestnikramn.spr-journal.ru/jour/article/view/131

Given the high rate of recurrence of ovarian cancer, the search for new therapeutic strategies are topical issue. According to various studies the effectiveness of drug treatment relapse depends on the platinum-free interval, increasing in proportion to its duration. If therapy is platinum-resistant recurrent ovarian cancer is a standard approach, the treatment of platinum-sensitive recurrent algorithm is not fully defined. Comparison of platinum and non-platinum combinations revealed the advantage of combined platinum- treatment for patients with platinum-free interval of more than 6 months without an increase in life expectancy. Non-platinum combination of trabectedin with pegylated liposomal doxorubicin has shown comparable efficacy with an advantage in overall survival in patients with platinum-free interval of 6–12 months. A platinum-free interval prolongation by the use of non-platinum mode increases the efficiency of subsequent platinum-based therapy, increasing the life expectancy of patients . Currently under study molecular markers and prognostic factors allowing to define a group of patients who have the greatest benefit from the use trabectedin with pegylated liposomal doxorubicin as second-line chemotherapy.

Учитывая высокую частоту рецидивирования рака яичника, поиск новых терапевтических стратегий представляется актуальным вопросом. По данным различных исследователей, эффективность лекарственного лечения рецидивов зависит от бесплатинового интервала, возрастая пропорционально его продолжительности. Если терапия платинорезистентных рецидивов рака яичника имеет стандартные подходы, то алгоритм лечения платиночувствительных рецидивов до конца не определен. Сравнение платиновых и неплатиновых комбинаций показало преимущество комбинированного платиносодержащего режима для больных с бесплатиновым интервалом более 6 мес без увеличения продолжительности жизни. Неплатиновая комбинация трабектедина с пегилированным липосомальным доксорубицином продемонстрировала сопоставимую эффективность с преимуществом по общей выживаемости в группе больных с бесплатиновым интервалом 6–12 мес, а пролонгирование бесплатинового интервала путем применения неплатинового режима повышает эффективность последующей платиносодержащей терапии, увеличивая продолжительность жизни больных. В настоящее время проводится исследование молекулярных маркеров и прогностических факторов, позволяющих определить группу больных, получающих наибольшую пользу от назначения трабектедина с пегилированным липосомальным доксорубицином во второй линии химиотерапии.

ovarian cancerplatinum-sensitive relapsetrabectedinрак яичникаплатиночувствительный рецидивтрабектедин1. Davydov M.I., Aksel' E.M. Statistics malignancies in Russia and the CIS in 2009. Vestn. RONTs = Bulletin of ROCC. 2011; 22 (3, App.1): 8–169.2. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., Jones W., Almadrones L., Lewis J.L., Jr. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 1991; 9: 389–393.3. Blackledge G., Lawton F., Redman C., Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Brit. J. Cancer. 1989; 59: 650–653.4. Gore M.E., Fryatt I., Wiltshaw E., Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 1990; 36: 207–211.5. Eisenhauer E.A., Vermorken J.B., van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments]. Ann. Oncol. 2011; 22 (Suppl. 8): 49–51. Doi: 10.1093/annonc/mdr467.6. Eisenhauer E.A. Optimal assessment of response in ovarian cancer. Oncol. Lett. 2010; 1 (6): 1021–1023.7. Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., Wheeler S., Swart A.M., Qian W., Torri V., Floriani I., Jayson G., Lamont A., Tropé C; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003; 361: 2099–2106.8. Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave J.A., Wagner U., Stahle A., Stuart G., Kimmig R., Olbricht S., Le T., Emerich J., Kuhn W., Bentley J., Jackisch C., Luck H.J., Rochon J., Zimmermann A.H., Eisenhauer E. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 2006; 24: 4699–4707.9. ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I., Broom C., Scarabelli C., Davidson N., Spanczynski M., Bolis G., Malmström H., Coleman R., Fields S.C., Heron J.F. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 1997; 15: 2183–2193.10. Trimble E.L., Adams J.D., Vena D., Hawkins M.J., Friedman M.A., Fisherman J.S., Christian M.C., Canetta R., Onetto N., Hayn R. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103. J. Clin. Oncol. 1993; 11: 2405–2410.11. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore E.M., Lacave J.A. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 2001; 19: 3312–3322.12. Cantù M.G., Buda A., Parma G., Rossi R., Floriani I., Bonazzi C., Dell'Anna T., Torri V., Colombo N. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J. Clin. Oncol. 2002; 20: 1232–1237.13. Cannistra S.A. Is there a «best» choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer. J. Clin. Oncol. 2002; 20: 1158–1160.14. Monk B.J., Herzog T., Kaye S., Krasner C.N., Vermorken J.B., Muggia F.M., Pujade-Lauraine E., Park Y.C., Parekh T.V., Poveda A.M. A randomized phase III study of trabectedin with pegylated liposomal doxorubicin versus PLD in relapsed, recurrent ovarian cancer. Proceedings of the 33rd Annual Meeting of the European Society of Medical Oncology. Stockholm. 2008. Abstract LBA3.15. D'Incalci M., Galmarini C.M. A review of trabectedin (ET-743): a unique mechanism of action. Mol. Cancer Ther. 2010; 9 (8): 2157–2163. Doi: 10.1158/1535-7163.MCT-10-0263.16. Monk B.J., Dalton H., Benjamin I., Tanović A. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer. Curr. Pharm. Des. 2012; 18 (25): 3754–3769.17. Shoji T., Takatori E., Kaido Y. et al. Usefulness of desensitization protocol for carboplatin hypersensitivity reaction during docetaxel-carboplatintherapy for recurrent ovarian cancer: Case report. 2012. Oncol. Lett. 2010;1 (6): 1021–1023.18. D'Incalci M., Galmarini C.M. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol. Cancer Ther. 2008; 7 (1): 10–18. Doi: 10.1158/1535-7163.MCT-07-0192.19. Avila M.A. Exploratory analysis of nibrin in advanced ovarian cancer (AOC) patients treated in the phase III OVA-301 trial. ASCO. 2013; abstr.5566.20. Kurman R.J., Shih I.-M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer. Shifting the Paradigm. Hum. Pathol. 2011; 42 (7): 918–931.21. Cannistra S.A. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J. Clin. Oncol. 2010; 28 (19): 3101–3103. Doi: 10.1200/JCO.2010.29.7077. Epub: 2010 Jun 1.22. Germano G., Frapolli R., Belgiovine C. et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013; 23 (2): 249–262. Doi: 10.1016/j.ccr.2013.01.008.23. Sehouli J., Alfaro V., González-Martín A. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives. Ann. Oncol. 2012; 23 (3): 556–562. Doi: 10.1093/annonc/mdr321.24. Soares D.G., Machado M.S., Rocca C.J. et al. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells. Mol. Cancer Ther. 2011; 10 (8): 1481–1489. Doi: 10.1158/1535-7163.MCT-11-0252.